RU2014113392A - METHOD FOR SUPPRESSING VISCOSITY REDUCTION OF A LIQUID WATER AGENT - Google Patents
METHOD FOR SUPPRESSING VISCOSITY REDUCTION OF A LIQUID WATER AGENT Download PDFInfo
- Publication number
- RU2014113392A RU2014113392A RU2014113392/15A RU2014113392A RU2014113392A RU 2014113392 A RU2014113392 A RU 2014113392A RU 2014113392/15 A RU2014113392/15 A RU 2014113392/15A RU 2014113392 A RU2014113392 A RU 2014113392A RU 2014113392 A RU2014113392 A RU 2014113392A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- aqueous preparation
- liquid aqueous
- pranoprofen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Способ подавления снижения вязкости жидкого водного препарата, содержащего гиалуроновую кислоту или ее фармацевтически приемлемую соль, включающий добавление к жидкому водному препарату пранопрофена или его фармацевтически приемлемой соли.2. Способ по п. 1, где фармацевтически приемлемая соль гиалуроновой кислоты представляет собой гиалуронат натрия.3. Способ по п. 1 или 2, включающий дополнительное добавление эдетовой кислоты или ее фармацевтически приемлемой соли.4. Способ по п. 3, где фармацевтически приемлемая соль эдетовой кислоты представляет собой натриевую соль эдетовой кислоты.5. Способ по п. 1, где концентрация гиалуроновой кислоты или ее фармацевтически приемлемой соли составляет 0,001-1,0% мас./об.6. Способ по п. 1, где добавление пранопрофена или его фармацевтически приемлемой соли производят таким образом, что концентрация пранопрофена или его фармацевтически приемлемой соли в жидком водном препарате составляет 0,001-1,0% мас./об.7. Способ по п. 1, где добавление пранопрофена или его фармацевтически приемлемой соли производят таким образом, что его соотношение в комбинации составляет 0,05-25 мас.ч. на 1 мас.ч. гиалуроновой кислоты или ее фармацевтически приемлемой соли.8. Способ по п. 1, где жидкий водный препарат представляет собой глазные капли.9. Агент подавления снижения вязкости для жидкого водного препарата, где агент содержит пранопрофен или его фармацевтически приемлемую соль и где жидкий водный препарат представляет собой жидкий водный препарат, содержащий гиалуроновую кислоту или ее фармацевтически приемлемую соль.1. A method of inhibiting a decrease in the viscosity of a liquid aqueous preparation containing hyaluronic acid or a pharmaceutically acceptable salt thereof, comprising adding pranoprofen or a pharmaceutically acceptable salt thereof to the liquid aqueous preparation. The method of claim 1, wherein the pharmaceutically acceptable salt of hyaluronic acid is sodium hyaluronate. A method according to claim 1 or 2, further comprising adding edetic acid or a pharmaceutically acceptable salt thereof. The method of claim 3, wherein the pharmaceutically acceptable salt of edetic acid is the sodium salt of edetic acid. The method of claim 1, wherein the concentration of hyaluronic acid or a pharmaceutically acceptable salt thereof is 0.001-1.0% w / v. 6. The method according to claim 1, wherein the addition of pranoprofen or a pharmaceutically acceptable salt thereof is produced in such a way that the concentration of pranoprofen or its pharmaceutically acceptable salt in a liquid aqueous preparation is 0.001-1.0% w / v. 7. The method according to claim 1, wherein the addition of pranoprofen or a pharmaceutically acceptable salt thereof is carried out in such a way that its combination ratio is 0.05-25 parts by weight. per 1 part by weight hyaluronic acid or a pharmaceutically acceptable salt thereof. 8. The method of claim 1, wherein the liquid aqueous preparation is eye drops. A viscosity reduction inhibition agent for a liquid aqueous preparation, wherein the agent contains pranoprofen or a pharmaceutically acceptable salt thereof and wherein the liquid aqueous preparation is a liquid aqueous preparation containing hyaluronic acid or a pharmaceutically acceptable salt thereof.
Claims (9)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011-194771 | 2011-09-07 | ||
JP2011194771 | 2011-09-07 | ||
PCT/JP2012/072877 WO2013035837A1 (en) | 2011-09-07 | 2012-09-07 | Method for suppressing decrease in viscosity of aqueous liquid agent |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2014113392A true RU2014113392A (en) | 2015-10-20 |
RU2598721C2 RU2598721C2 (en) | 2016-09-27 |
Family
ID=47832277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2014113392/15A RU2598721C2 (en) | 2011-09-07 | 2012-09-07 | Method for suppressing decrease in viscosity of aqueous liquid agent |
Country Status (5)
Country | Link |
---|---|
JP (2) | JP6376550B2 (en) |
KR (1) | KR20140059276A (en) |
CN (1) | CN103796653B (en) |
RU (1) | RU2598721C2 (en) |
WO (1) | WO2013035837A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102051356B1 (en) * | 2019-01-03 | 2019-12-03 | (주)휴온스 | Eye drop composition containing high concentration of hyaluronic acid or its salt |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1283911B1 (en) * | 1996-02-05 | 1998-05-07 | Farmigea Spa | VISCOSIZED OPHTHALMIC SOLUTIONS WITH TAMARIND GUM POLYSACCHARIDES |
JPH115744A (en) * | 1997-06-16 | 1999-01-12 | Toa Yakuhin Kk | Aqueous solution preparation for external use containing hyaluronic acid |
JP4789479B2 (en) * | 2004-02-23 | 2011-10-12 | ロート製薬株式会社 | Planoprofen-containing aqueous composition |
JP4831944B2 (en) * | 2004-04-28 | 2011-12-07 | ロート製薬株式会社 | Planoprofen-containing composition |
JP2006176457A (en) * | 2004-12-24 | 2006-07-06 | Wakamoto Pharmaceut Co Ltd | Aqueous liquid composition for medicinal use |
JP4919666B2 (en) * | 2005-01-26 | 2012-04-18 | ロート製薬株式会社 | Planoprofen-containing composition |
JP4989898B2 (en) * | 2005-01-26 | 2012-08-01 | ロート製薬株式会社 | Planoprofen-containing composition |
JP2006248960A (en) * | 2005-03-10 | 2006-09-21 | Rohto Pharmaceut Co Ltd | Aqueous composition for external use |
JP5258329B2 (en) * | 2007-06-01 | 2013-08-07 | ロート製薬株式会社 | Planoprofen-containing aqueous pharmaceutical composition |
JP2010132608A (en) * | 2008-12-05 | 2010-06-17 | Wakamoto Pharmaceut Co Ltd | Aqueous liquid composition for pharmaceutical-use |
-
2012
- 2012-09-07 JP JP2013532668A patent/JP6376550B2/en active Active
- 2012-09-07 WO PCT/JP2012/072877 patent/WO2013035837A1/en active Application Filing
- 2012-09-07 KR KR1020147008749A patent/KR20140059276A/en not_active Application Discontinuation
- 2012-09-07 CN CN201280043160.3A patent/CN103796653B/en active Active
- 2012-09-07 RU RU2014113392/15A patent/RU2598721C2/en active
-
2017
- 2017-02-01 JP JP2017016564A patent/JP6376624B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP6376624B2 (en) | 2018-08-22 |
CN103796653A (en) | 2014-05-14 |
WO2013035837A1 (en) | 2013-03-14 |
KR20140059276A (en) | 2014-05-15 |
JPWO2013035837A1 (en) | 2015-03-23 |
RU2598721C2 (en) | 2016-09-27 |
JP2017101054A (en) | 2017-06-08 |
JP6376550B2 (en) | 2018-08-22 |
CN103796653B (en) | 2016-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017006975A (en) | Water-enhancing, fire-suppressing hydrogels. | |
WO2013037479A8 (en) | Ophthalmic compositions comprising prostaglandin f2 alpha derivatives and hyaluronic acid | |
MX2016007661A (en) | Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof. | |
EA201590371A1 (en) | 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS | |
MX2020000404A (en) | Syk inhibitors. | |
UA113981C2 (en) | Ophthalmic solution containing diquafasol | |
UA102257C2 (en) | Ophthalmic aqueous composition for treating ocular hypertension and glaucoma | |
BR112013026355A2 (en) | tri- and tetracyclic pyrazolo [3,4-b] pyridine compounds as antineoplastic agent | |
EA201492204A1 (en) | NUCLEOSIDES BASED ON URACIL AND SPIROOXETANE | |
AR089962A1 (en) | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR ELABORATION AND USE | |
NZ712302A (en) | Biocidal composition and method for treating water or surfaces in contact with water | |
UA113962C2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING APOMORPHINE AS AN ACTIVE INGREDIENT | |
EA201401259A1 (en) | FLUORINATED BRIDGES DERIVATIVES OF SPIRO [2,4] HEPTANA AS AGONISTS OF ALX RECEPTOR | |
EA201492091A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR LOCAL APPLICATION CONTAINING TERBINAPHID AND UREA | |
RU2018102693A (en) | Ophthalmic compositions containing cooperative complexes of low and high molecular weight hyaluronic acid | |
MY161032A (en) | Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate | |
WO2013101911A3 (en) | Benzimidazole derivatives as selective blockers of persistent sodium current | |
IN2013MU03773A (en) | ||
MX368017B (en) | Indazole compounds as 5-ht4 receptor agonists. | |
EA201691825A1 (en) | STABILIZED SOLUTION ON THE BASIS OF ACTIVE SUBSTANCES, METHOD FOR OBTAINING A STABILIZED SOLUTION OF ACTIVE SUBSTANCES, PHARMACEUTICAL COMPOSITION ON THE BASIS OF A STABILIZED SOLUTION OF ACTIVE SUBSTANCES (TWO OPTIONS) | |
RU2014113392A (en) | METHOD FOR SUPPRESSING VISCOSITY REDUCTION OF A LIQUID WATER AGENT | |
MY176112A (en) | Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol | |
EA201490360A1 (en) | COMPOSITIONS CONTAINING AMINO ACID SALTS | |
EA201490363A1 (en) | NEW COMPOSITIONS BASED ON (TRIMETOXYPHENYLAMINO) Pyrimidinyls | |
BR112017014016A2 (en) | intraocular pressure reduction method; and, pharmaceutical composition. |